THERAPY DOSSIER · th-3f1e70908f9b

KZ-41 (quinic acid derivative)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24648047 ↗2013Reported benefit

Quinic acid derivative KZ-41 exhibits radiomitigating activity in preclinical models of radiation injury.

MouseRadiationC57BL/6FemaleSubcutaneous for the survival study; intraperitoneal for the vascular injury study100 mg/kgApproximately 26 h after total body irradiation in the survival study; 12, 36 a…

Model: Total body irradiation (137Cs) acute radiation syndrome, and combined total body irradiation with dorsal window postcapillary venule injury

KZ-41 increased 30-day survival by approximately 45% relative to vehicle after lethal total body irradiation (P<0.05) and increased clot formation after radiation-induced venule injury (P<0.05), although blood flow was not improved.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…